Media stories about Patheon NV (NASDAQ:PTHN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Patheon NV earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.9420058492378 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Patheon NV (PTHN) opened at 34.90 on Tuesday. The stock has a market capitalization of $5.07 billion and a PE ratio of 44.74. The company’s 50-day moving average price is $34.25 and its 200 day moving average price is $29.80. Patheon NV has a 52-week low of $23.72 and a 52-week high of $35.10.
Patheon NV (NASDAQ:PTHN) last posted its quarterly earnings results on Thursday, June 8th. The company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.01. The business had revenue of $483.40 million for the quarter, compared to the consensus estimate of $466.08 million. Patheon NV’s revenue was up 3.2% compared to the same quarter last year. Equities analysts forecast that Patheon NV will post $1.14 EPS for the current fiscal year.
PTHN has been the topic of several research reports. Zacks Investment Research lowered Patheon NV from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 22nd. Jefferies Group LLC lowered Patheon NV from a “buy” rating to a “hold” rating and boosted their target price for the company from $32.00 to $35.00 in a research note on Tuesday, May 16th. Piper Jaffray Companies lowered Patheon NV from an “overweight” rating to a “neutral” rating in a research note on Monday, May 15th. William Blair lowered Patheon NV from an “outperform” rating to a “market perform” rating in a research note on Monday, May 15th. Finally, Evercore ISI lowered Patheon NV to an “outperform” rating and set a $35.00 target price on the stock. in a research note on Monday, May 15th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $32.88.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Patheon NV (NASDAQ:PTHN) Stock Price” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2017/07/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-patheon-nv-nasdaqpthn-stock-price.html.
Patheon NV Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.